Compare KRP & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRP | VIR |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2017 | 2019 |
| Metric | KRP | VIR |
|---|---|---|
| Price | $13.54 | $7.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $17.00 | ★ $28.63 |
| AVG Volume (30 Days) | 661.4K | ★ 1.9M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 12.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $315,520,668.00 | $16,860,000.00 |
| Revenue This Year | $5.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.98 | $4.16 |
| 52 Week High | $16.14 | $10.67 |
| Indicator | KRP | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 55.29 |
| Support Level | $12.04 | $7.25 |
| Resistance Level | $13.63 | $7.97 |
| Average True Range (ATR) | 0.29 | 0.50 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 95.00 | 66.24 |
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.